| Decnupaz | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | Phase 2 | Active not recruiting | 218 | Feb 2027 |
| MEDI0618 | A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine | Phase 2 | Active not recruiting | 309 | Feb 2027 |
| Elahere | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | Phase 2 | Active not recruiting | 108 | Feb 2027 |
| Upadacitinib | Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | Phase 3 | Active not recruiting | 99 | Jan 2027 |
| Livmoniplimab | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | Phase 3 | Active not recruiting | 89 | Jan 2027 |
| Ranibizumab (LUCENTIS®) | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | Phase 3 | Active not recruiting | 671 | Dec 2026 |
| Temab-A | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | Phase 2 | Active not recruiting | 280 | Dec 2026 |
| lutikizumab | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 1,400 | Dec 2026 |
| Elahere | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer | Phase 2 | Active not recruiting | 125 | Nov 2026 |
| — | A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants | Phase 3 | Completed | 252 | Sep 3, 2026 |
| ABBV-444 | A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease | Phase 3 | Completed | 261 | Aug 21, 2026 |
| Eluxadoline | Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children | Phase 2 | Completed | 272 | Aug 17, 2026 |
| Venclexta | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. | Phase 3 | Active not recruiting | 265 | Aug 2026 |
| Ranibizumab | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 | Active not recruiting | 146 | Aug 2026 |
| GM-2505 | A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD | Phase 2 | Completed | 126 | Jul 27, 2026 |
| Humira | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis | Phase 3 | Completed | 487 | Jul 15, 2026 |
| — | ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars | Phase 3 | Completed | 157 | Jul 14, 2026 |
| Telisotuzumab vedotin | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | 270 | Jul 2026 |
| Bimatoprost SR | Long-term Safety and Efficacy Extension Trial of Bimatoprost SR | Phase 3 | Completed | 455 | Jun 19, 2026 |
| Topical Steroid | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) | Phase 2 | Completed | 139 | Jun 18, 2026 |
| Venclexta | Venetoclax After TKI to Target Persisting Stem Cells in CML | Phase 2 | Completed | 10 | May 31, 2026 |
| ABBV-951 | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease | Phase 3 | Completed | 118 | Apr 27, 2026 |
| ABBV-951 | Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease | Phase 3 | Completed | 130 | Apr 17, 2026 |
| OnabotulinumtoxinA | A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants | Phase 3 | Completed | 150 | Apr 3, 2026 |
| Memantine | Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus | Phase 2 | Completed | 111 | Feb 28, 2026 |
| — | A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality | Phase 3 | Completed | 135 | Feb 5, 2026 |
| — | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma | Phase 3 | Completed | 74 | Feb 4, 2026 |
| Venclexta | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | Phase 2 | Terminated | 51 | Feb 3, 2026 |
| Elezanumab | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) | Phase 2 | Completed | 60 | Jan 26, 2026 |
| — | A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants | Phase 3 | Completed | 61 | Dec 5, 2025 |
| Juvmo | Open-label Trial in Parkinson's Disease (PD) | Phase 3 | Completed | 992 | Dec 1, 2025 |
| BOTOX | A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence | Phase 3 | Completed | 202 | Nov 25, 2025 |
| — | Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | Phase 2 | Completed · results | 194 | Nov 17, 2025 |
| ABBV-932 | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder | Phase 2 | Completed | 161 | Nov 12, 2025 |
| BOTOX | A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants | Phase 3 | Completed | 207 | Nov 10, 2025 |
| Venclexta | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Phase 2 | Completed · results | 20 | Oct 9, 2025 |
| Venclexta | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) | Phase 3 | Terminated · results | 465 | Sep 23, 2025 |
| ABBV-382 | A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382 | Phase 2 | Terminated · results | 163 | Sep 22, 2025 |
| Linzess | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation | Phase 3 | Completed · results | 123 | Sep 2, 2025 |
| Bimatoprost (SR) | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | Phase 3 | Completed · results | 515 | Aug 8, 2025 |